TY - JOUR T1 - Compartmental and Enzyme Kinetic Modeling To Elucidate the Biotransformation Pathway of a Centrally Acting Antitrypanosomal Prodrug JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 518 LP - 528 DO - 10.1124/dmd.112.048231 VL - 41 IS - 2 AU - Claudia N. Generaux AU - Garrett R. Ainslie AU - Arlene S. Bridges AU - Mohamed A. Ismail AU - David W. Boykin AU - Richard R. Tidwell AU - Dhiren R. Thakker AU - Mary F. Paine Y1 - 2013/02/01 UR - http://dmd.aspetjournals.org/content/41/2/518.abstract N2 - DB868 [2,5-bis [5-(N-methoxyamidino)-2-pyridyl] furan], a prodrug of the diamidine DB829 [2,5-bis(5-amidino-2-pyridyl) furan], has demonstrated efficacy in murine models of human African trypanosomiasis. A cross-species evaluation of prodrug bioconversion to the active drug is required to predict the disposition of prodrug, metabolites, and active drug in humans. The phase I biotransformation of DB868 was elucidated using liver microsomes and sandwich-cultured hepatocytes from humans and rats. All systems produced four NADPH-dependent metabolites via O-demethylation (M1, M2) and N-dehydroxylation (M3, M4). Compartmental kinetic modeling of the DB868 metabolic pathway suggested an unusual N-demethoxylation reaction that was supported experimentally. A unienzyme Michaelis-Menten model described the kinetics of M1 formation by human liver microsomes (HLMs) (Km, 11 μM; Vmax, 340 pmol/min/mg), whereas a two-enzyme model described the kinetics of M1 formation by rat liver microsomes (RLMs) (Km1, 0.5 μM; Vmax1, 12 pmol/min/mg; Km2, 27 μM; Vmax2, 70 pmol/min/mg). Human recombinant CYP1A2, CYP3A4, and CYP4F2, rat recombinant Cyp1a2 and Cyp2d2, and rat purified Cyp4f1 catalyzed M1 formation. M2 formation by HLMs exhibited allosteric kinetics (S50, 18 μM; Vmax, 180 pmol/mg), whereas M2 formation by RLMs was negligible. Recombinant CYP1A2/Cyp1a2 catalyzed M2 formation. DB829 was detected in trace amounts in HLMs at the end of the 180-min incubation and was detected readily in sandwich-cultured hepatocytes from both species throughout the 24-h incubation. These studies demonstrated that DB868 biotransformation to DB829 is conserved between humans and rats. An improved understanding of species differences in the kinetics of DB829 formation would facilitate preclinical development of a promising antitrypanosomal prodrug. ER -